News 2004

News 2005

News 2006

Crionna Oversee Gene Therapy Phase III Studies

16 January 2006 Crionna signed a contract with an upcoming US Biotechnology company developing a novel genetically modified cellular Immunotherapy for prostate cancer. Crionna took responsibility for overseeing the activities of the two Companies selected to run the studies. The studies are taking place in over 110 hospitals in 8 European countries to compliment a similarly sized US program.

Crionna will be responsible for harmonisation between the Europeans teams and their US counterparts and assist in the optimisation of the clinical program and investigator training.

The Crionna Team are delighted to have the opportunity to work on such an exciting program which will involve overcoming significant hurdles related to the newly introduced Biosafety Committee reviews required for GMO products.

Crionna Sign Contract for Web Based Data Collection System for NHS Group

20 June 2006 The Crionna data management group have teamed up with NHS Consultants to design a web based data collection system. Information from over 10 hospitals throughout the UK will be entered locally into the system, enabling central review. It is hoped that this system will improve on existing paper based systems and lead to improved patient management.